Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01650545 · ClinicalTrials.gov registry record · Phase 1
Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01650545 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 21 participants.
The verdict
NCT01650545, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A in the treatment of chronic rejection in lung transplant recipients with bronchiolitis obliterans syndrome (BOS). The primary objective is to evaluate the efficacy of liposomal cyclosporine A in the treatment of chronic rejection. Pulmonary function and changes in BOS grade are the primary end points.
Interventions
- DRUG Liposomal aerosol cyclosporine
- OTHER standard immune suppression, oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-07 |
| Est. Completion | 2019-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01650545
The ClinicalTrials.gov registry entry for NCT01650545 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal aerosol cyclosporine is the first listed.
NCT01650545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01650545 about?
NCT01650545 is a clinical study titled "Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients". This is a single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A in the treatment of chronic rejection in lung transplant recipients with bronchiolitis obliterans syndrome (BOS). The primary objective is to evaluate the efficacy of liposomal cyclosp...
What is the current status of trial NCT01650545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2012-07. Estimated completion is 2019-11.
What interventions are being tested in trial NCT01650545?
The interventions under investigation include: Liposomal aerosol cyclosporine (DRUG), standard immune suppression, oral (OTHER).
Who is sponsoring clinical trial NCT01650545?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.